DRIVE - Desmopressin for procedures or Radiological InterVEntions
Research type
Research Study
Full title
A placebo-controlled double blind, randomised feasibility trial of Desmopressin (DDAVP) in critical illness prior to procedures.
IRAS ID
204449
Contact name
Dr Michael Desborough
Contact email
Sponsor organisation
NHS Blood and Transplant
Eudract number
2016-001126-33
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
People with low platelet counts are vulnerable to bleeding. Approximately one third of patients in Intensive Care have a low platelet count and the majority undergo at least one interventional procedure during their admission, which further increases their bleeding risk. Desmopressin is a licensed drug which is commonly used for congenital bleeding disorders such as Haemophilia and von Willebrand disease and it has a well-known safety profile, and few adverse effects. In this trial, patients will be randomised to either receive demopressin or placebo prior to undergoing a procedure (in addition to standard care).
This trial is primarily looking at the feasibility of administering desmopressin in this setting, but several measures of efficacy will also be looked at. These include laboratory tests to check platelet function, bleeding events and the need for blood products (red cells, platelets) after the procedure.
REC name
South Central - Oxford C Research Ethics Committee
REC reference
16/SC/0524
Date of REC Opinion
29 Nov 2016
REC opinion
Further Information Favourable Opinion